Listen to Howard Marks, David Rosenberg, and Aman Kumar as they discuss the concept of normalcy in financial markets and interest rates, the challenge of changing perspectives, factors driving the market rally, monitoring consumer spending, and the volatility in the life sciences public equity market.

Aman Kumar, Oaktree's managing director, discusses direct lending in the life science sector, public-to-private transaction opportunities, and Oaktree's private credit strategy. He explores various sub-sectors within life sciences, attractive investment areas like immuno-oncology, and key markets. Kumar explains deal structuring, equity upside participation, leverage complexities, and pricing structure in life sciences lending. He also discusses conservative spending, non-dilutive financing in biotech and bio pharma markets, and the increase in public to private deals in the sector.

Howard Marks, David Rosenberg, and Aman Kumar discuss the challenge of resetting one's idea of normal in financial markets. They explore the drivers behind the recent market rally and the potential pivot of the Fed. The speakers also highlight the risks and trends for 2024, including consumer spending and an exciting trade opportunity. They delve into the shifts in the life sciences public equity market, exploring volatile valuations and non-dilutive financing opportunities.